Orgenesis Hosts Q2 2022 Business Update Conference Call

Orgenesis Inc.

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotechnology company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 a.m. Tuesday, August 16, 2022 to discuss company progress and other developments.

The conference call will be available by phone by dialing toll-free 888-506-0062 for US callers or +1 973-528-0011 for international callers and using the passcode 223911. A webcast of the call can be viewed at or on the Company’s Investor Events section of the website here.

A webcast replay will be available in the Company’s Investor Events section of the website ( through Wednesday, August 16, 2023. A telephone replay of the call will be available approximately one hour after the call, until Tuesday, August 30, 2022 and accessible by dialing 877-481-4010 for US callers or +1 919-882-2331 for international callers and entering the ID conference: 46399.

About Orgenesis
Orgenesis is a global biotechnology company dedicated to unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible point-of-care format. The Orgenesis POCare platform is comprised of three enabling components: a pipeline of licensed POCare therapeutics that are processed and produced in closed, automated POCare technology systems on a collaborative POCare network. Orgenesis identifies promising new therapies and leverages its POCare platform to provide a fast, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lower cost through efficient production, scalable and decentralized. The POCare Network brings together patients, physicians, industry partners, research institutes and hospitals worldwide to achieve harmonized and regulated clinical development and production of therapies.

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as than amended. These forward-looking statements involve substantial risks and uncertainties and are based on our current expectations, estimates and projections and reflect our beliefs and assumptions based on information available to us as of the date of this press release. We caution readers that forward-looking statements are predictions based on our current expectations regarding future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements due to a number of factors, including, but not limited to, our ability to further develop ranpirnase; our dependence on our point-of-care cell therapy platform and our ability to develop it; our ability to develop cellular and antiviral technologies; our ability to effectively utilize net proceeds from the sale of Masthercell; our ability to achieve and maintain overall profitability; the development of our POCare strategy; the sufficiency of working capital to execute our business plans; the ability of our partners to develop therapies based on our point-of-care cell therapy platform; the technology is not working as expected; our ability to retain key employees; our ability to meet stringent regulatory requirements for new procedures and therapies; our competitors developing better or cheaper alternatives; the impact of COVID-19 on our operations and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
[email protected]

Communication contact for Orgenesis
Image box communication
Neil Hunter/Michelle Boxall
Tel +44 (0)20 8943 4685
[email protected] / [email protected]

Michael P. Boser